Can Fite BioPharma Stock Price - CANF

Best deals to access real time data!
Canadian Level 1 + USA
Monthly Subscription
for only
CHART Trader
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Last Trade
Last $ 2.35 ▲ 0.05 (2.17%)
Company Name Stock Ticker Symbol Market Type
Can Fite BioPharma Ltd CANF AMEX Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.0% 2.30 0.00 0.00 0.00 2.30 08:39:41
Stock Trades Traded Volume Average Volume 52 Week Range
7 501 288,656 0.38 - 8.8765
Last Trade Time Type Quantity Stock Price Currency
08:38:26 22 $ 2.35 USD

Can Fite BioPharma Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 9.25M 4.02M $ -6.57M -5.10 - 4.02M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
246.18k $ - 0.00% - -

more financials information »

Can Fite BioPharma News

Loading Messages....

Latest CANF Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CANF Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.802.902.232.4593,116-0.50-17.86%
1 Month3.334.472.233.08320,103-1.03-30.93%
3 Months2.394.952.233.51437,139-0.09-3.77%
6 Months2.945.611.903.07362,992-0.64-21.77%
1 Year1.168.87650.382.39359,2861.1498.28%
3 Years1.918.87650.382.09189,8840.3920.42%
5 Years3.428.87650.383.23312,586-1.12-32.75%

Can Fite BioPharma Description

Can Fite Biofarma Ltd is a clinical-stage biopharmaceutical company. The company is focused on developing orally bioavailable small molecule therapeutic products for the treatment of autoimmune inflammatory indications, oncology and liver diseases as well as sexual dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention. The company's pipeline drugs are synthetic, specific agonists and allosteric modulators targeting the A3AR. All drugs are orally bioavailable with an excellent safety profile.

Your Recent History
Can Fite B..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.